Addex Therapeutics
ADXN
Addex Therapeutics (ADXN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.44
- EPS estimate
- $0.00
- EPS surprise
- +0.00%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 26, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 26, 2026 | $0.00 | −$1.44 | +0.00% | $0.00 | SEC |
| Q1 2026 | Jun 25, 2026 | $0.00 | −$1.48 | +0.00% | $9,878.00 | SEC |
| Q3 2025 | Dec 4, 2025 | $0.00 | −$1.50 | +0.00% | $62,426.00 | SEC |
| Q2 2025 | Sep 30, 2025 | $0.00 | −$3.02 | +0.00% | $45,246.00 | SEC |
| Q3 2024 | Nov 22, 2024 | −$1.42 | −$2.69 | −89.15% | $66,014.00 | SEC |
| Q2 2024 | Sep 30, 2024 | −$1.42 | $11.38 | +899.25% | $136,329.00 | SEC |
| Q1 2024 | Jun 6, 2024 | −$0.44 | −$1.35 | −204.69% | $263,438.00 | SEC |
| Q3 2023 | Nov 29, 2023 | −$0.66 | −$4.11 | −521.24% | $376,022.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.83 | −$5.49 | −565.81% | $723,319.00 | SEC |
| Q1 2023 | May 11, 2023 | −$1.03 | −$5.37 | −420.36% | $561,301.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$1.03 | −$27.60 | −2575.66% | $655,971.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$1.86 | $11.42 | +715.08% | $439,816.00 | — |
| Q2 2022 | Aug 18, 2022 | −$2.71 | −$23.89 | −782.91% | $194,897.00 | — |
| Q1 2022 | May 5, 2022 | −$10.33 | −$18.27 | −76.94% | $247,678.00 | — |
| Q4 2021 | Mar 10, 2022 | −$12.98 | −$16.30 | −25.56% | $419,062.00 | — |
| Q3 2021 | Nov 4, 2021 | −$17.05 | −$14.46 | +15.21% | $830,366.00 | — |
| Q2 2021 | Aug 5, 2021 | −$15.75 | −$18.53 | −17.62% | $1.2M | — |
| Q1 2021 | May 5, 2021 | −$13.13 | −$10.51 | +19.93% | $1.0M | — |
| Q4 2020 | Mar 11, 2021 | $0.00 | −$10.50 | +0.00% | $2.1M | — |
| Q3 2020 | Nov 3, 2020 | $0.00 | −$15.78 | +0.00% | $109,607.00 | — |
Quarterly revenue
Frequently asked questions
When did Addex Therapeutics (ADXN) last report earnings?
Addex Therapeutics last reported on Aug 26, 2026, covering fiscal Q2 2026.
Did ADXN beat earnings estimates?
Addex Therapeutics reported EPS of −$1.44 for Q2 2026, in line with the $0.00 consensus estimate.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.